Skip Navigation


Wegeners Granulomatosis Etanercept Trial (WGET)

WGET was a randomized, double-masked, placebo-controlled clinical trial. The primary objective of the trial was to evaluate the efficacy and safety of etanercept (Enbrel™; Immunex Corporation, Seattle, WA) in the induction and maintenance of disease remissions for patients with Wegener’s Granulomatosis (WG), when used in conjunction with standard treatment. A secondary objective was to develop a specimen bank of blood samples that may be used to address basic questions regarding the etiology, pathophysiology, and monitoring of WG. The sample size was 180 patients, to be recruited from 8 clinical centers in the United States over a 30-month period.


Study Website


© , Johns Hopkins University. All rights reserved.
Web policies, 615 N. Wolfe Street, Baltimore, MD 21205